SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Operating Expenses of $9.3 million for Q1 2026, up 52.6% year-over-year from $6.1 million in Q1 2025, and up 12.08% quarter-over-quarter from $8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Operating Expenses for 17 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 52.6% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $31.5 million (up 12.65% YoY), while the FY2025 annual figure was $28.3 million, down 10.28% from the prior year.
- Operating Expenses grew to $9.3 million in Q1 2026 per SLS's latest filing, from $8.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $17.7 million in Q1 2022 and bottomed at $6.1 million in Q1 2025.
- Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $8.3 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 123.22% — and 2025, when it tumbled 37.14%.
- SELLAS Life Sciences' Operating Expenses stood at $9.4 million in 2022, then slipped by 13.43% to $8.2 million in 2023, then slipped by 15.4% to $6.9 million in 2024, then rose by 19.33% to $8.3 million in 2025, then gained by 12.08% to $9.3 million in 2026.
- Business Quant data shows SLS's Operating Expenses at $9.3 million in Q1 2026, $8.3 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 10.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.63 Mn |
| Mar 31, 2026 | 9.25 Mn |
| Dec 31, 2025 | 8.26 Mn |
| Sep 30, 2025 | 7.08 Mn |
| Jun 30, 2025 | 6.87 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Sep 30, 2024 | 7.33 Mn |
| Jun 30, 2024 | 7.62 Mn |
| Mar 31, 2024 | 9.65 Mn |
| Dec 31, 2023 | 8.18 Mn |
| Sep 30, 2023 | 9.36 Mn |
| Jun 30, 2023 | 9.05 Mn |
| Mar 31, 2023 | 11.28 Mn |
| Dec 31, 2022 | 9.45 Mn |
| Sep 30, 2022 | 7.15 Mn |
| Jun 30, 2022 | 8.62 Mn |
| Mar 31, 2022 | 17.74 Mn |
| Dec 31, 2021 | 11.62 Mn |
| Sep 30, 2021 | 6.98 Mn |